ArticleBMC cardiovascular disorders2025
The correlation between serum vitamin D with Apo B and framingham risk score among a group of Iraqi subjects: a Cross-sectional and prospective pilot study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: The correlation between serum vitamin D with Apo B and framingham risk score among a group of Iraqi subjects: a cross-sectional and prospective pilot study.BMC cardiovascular disorders · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D may play a role in cardiovascular health, particularly in lipid metabolism and atherosclerosis. This study examines the correlation between serum vitamin D levels with Apolipoprotein B (Apo B), and the Framingham Risk Score (FRS) and evaluates the impact of correcting severe vitamin D deficiency on Apo B levels and FRS among a group of Iraqi population.
methodsThis two-phase study was conducted in Baghdad between November 2022 and October 2023 and included a cross-sectional phase examining the association between vitamin D, with Apo B, and the FRS, followed by a prospective phase assessing the impacts of vitamin D correction. A total of 201 participants were recruited, including 60 individuals with severe vitamin D deficiency (≤ 10 ng/ml) who received supplementation and 40 with sufficient vitamin D levels (≥ 30 ng/ml) serving as controls. Levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), Apo B, and FRS were evaluated at baseline and after six months. The Thai Clinical Trials Registry (TCTR) has retrospectively registered and approved the study under the identification number TCTR20250301003 on the 1st of March 2025.
resultsVitamin D levels correlated significantly with age (p < 0.001), Apo B (p = 0.007), and FRS (p = 0.003) in the cross-sectional phase. After supplementation TC (p = 0.004) and FRS (p = 0.007) significantly decreased in the treatment group, with no significant changes in Apo B. Males only showed significant decrease in FRS and TC.
conclusionVitamin D correction significantly decreased TC and FRS reinforcing its role in lipid metabolism and cardiovascular health. However, Apo B levels remained unchanged, suggesting that vitamin D may not directly influence Apo B metabolism in the short term. These findings emphasize the importance of correcting severe vitamin D deficiency before calculating FRS due to its impact on lipid parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.